Literature DB >> 28736017

Long-term Outcomes for Liver Transplant Recipients in Terms of Hepatic Encephalopathy.

D D You1, G S Choi2, J M Kim3, C H D Kwon3, J-W Joh3, S-K Lee3.   

Abstract

BACKGROUND: Liver transplantation (LT) is thought to resolve cognitive deficit due to hepatic encephalopathy (HE). The aim of this study was to determine the factors associated with the outcomes of patients with HE after LT.
METHODS: The authors reviewed the medical records of 388 patients with HE who underwent LT from 1996 to 2014.
RESULTS: There were 282 patients with grade 1-2 HE and 106 patients classified as grade 3-4. Patients in the latter group had a tendency for a more decompensated hepatic condition than patients with grade 1-2 HE. HE sequelae were only associated with grade 3-4 HE with borderline significance (P = .05). The cumulative 1-, 3-, and 5-year overall survival (OS) of patients with grade 1-2 HE were 81.9%, 77.3%, and 74.6%, whereas those of in patients with grade 3-4 HE were 77.4%, 73.3%, and 72.2%, respectively (P = .75).
CONCLUSION: The sequelae of HE were only associated with the grade 3-4 HE. Aggressive treatment of HE prior to LT may prevent patients from deteriorating into high-grade HE, which could further contribute to improving the outcomes after LT.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28736017     DOI: 10.1016/j.transproceed.2017.02.054

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Therapeutic potential of probiotics - Lactobacillus plantarum UBLP40 and Bacillus clausii UBBC07 on thioacetamide-induced acute hepatic encephalopathy in rats.

Authors:  Lalita Shahgond; Chirag Patel; Khushboo Thakur; Dipta Sarkar; Sanjeev Acharya; Priyanshi Patel
Journal:  Metab Brain Dis       Date:  2021-11-03       Impact factor: 3.584

Review 2.  Cognitive Function in Liver Transplantation.

Authors:  Somaya A M Albhaisi; Jasmohan S Bajaj
Journal:  Curr Transplant Rep       Date:  2020-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.